Does Ozempic Cause Diarrhea? When It Happens and Why

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• STEP 1 reported diarrhea in 31.5% of semaglutide 2.4 mg participants vs 15.9% on placebo
• Diarrhea is dose-related and most common in the first 4 to 6 weeks after starting or after each titration step
• Some patients experience constipation, others diarrhea, and some oscillate; gut motility effects are individually variable
• High-fat meals, sugar alcohols, alcohol, and lactose are the most common dietary triggers
• Most cases respond to dietary modification, hydration, and time; loperamide is reasonable for occasional use

Direct answer

Yes. Semaglutide produces diarrhea in roughly one-third of users at the 2.4 mg dose, per STEP 1 data. It is less commonly discussed than nausea but is among the most frequent GI side effects. The pattern is usually mild to moderate, dose-related, and self-limited within 4 to 6 weeks of dose stabilization. Severe or persistent diarrhea is uncommon and usually responds to dose reduction or dietary adjustment.

Table of contents

1. The trial data
2. Why semaglutide can cause both diarrhea and constipation
3. The dose-response pattern
4. Food triggers worth identifying
5. Lactose, fructose, and sugar alcohol contributions
6. Management: dietary, OTC, and prescription
7. When diarrhea is something else
8. The tirzepatide comparison
9. Hydration and electrolyte considerations
10. Decision framework
11. FAQ
12. Sources

The trial data

The STEP 1 adverse event profile for diarrhea (Wilding et al., NEJM 2021):

Population	Diarrhea incidence
Semaglutide 2.4 mg	31.5%
Placebo	15.9%
Difference	+15.6 percentage points

Diarrhea ranks as the second most common GI adverse event after nausea. The "ever during trial" rate of 31.5% reflects any episode counted over 68 weeks; point prevalence at any given week is much lower, typically 5 to 10% of patients actively experiencing diarrhea.

SURMOUNT-1 reported similar rates with tirzepatide: 19% to 23% diarrhea depending on dose, versus 9% placebo. The pattern is consistent across the GLP-1 class.

Why semaglutide can cause both diarrhea and constipation

The seemingly paradoxical observation that some patients have constipation and others have diarrhea on the same medication reflects the complexity of gut motility regulation.

Semaglutide acts on multiple targets:

• Slows gastric emptying (consistent across patients)
• Modulates small intestinal motility (variable; can slow or speed)
• Affects colonic motility (variable)
• Alters bile acid secretion (can produce bile acid diarrhea in some patients)
• Changes appetite and food selection (which secondarily affects stool consistency)

The net effect depends on individual baseline gut function. Patients with sluggish baseline transit may experience constipation. Patients with faster baseline transit, particularly those with irritable bowel syndrome subtypes that lean toward diarrhea, may experience worse diarrhea on the medication.

Bile acid effects deserve specific attention. Semaglutide may increase bile acid delivery to the colon in some patients, producing watery diarrhea that responds to bile acid sequestrants like cholestyramine. This subtype is underdiagnosed.

The dose-response pattern

Diarrhea incidence increases with dose:

Dose	Approximate diarrhea rate
0.25 mg (starting dose)	10-15%
0.5 mg	15-20%
1.0 mg	20-25%
1.7 mg	25-28%
2.4 mg	30-32%

Patients who experience problematic diarrhea on a higher dose often tolerate a lower dose well. Holding at 1.0 mg or 1.7 mg rather than continuing to 2.4 mg is a reasonable approach for patients prioritizing tolerability over maximum weight loss.

Food triggers worth identifying

The most reproducible dietary triggers for diarrhea on a GLP-1:

High-fat meals. Fat normally requires gradual breakdown by pancreatic enzymes and bile. When the small intestine receives more fat than it can process (due to large fat loads or relative pancreatic insufficiency), the unabsorbed fat reaches the colon and causes osmotic and steatorrheic diarrhea. Fried foods, cream sauces, and fatty meats are the worst.

Sugar alcohols. Sorbitol, xylitol, erythritol, and maltitol are common in sugar-free candy, gum, protein bars, and "diet" products. They draw water into the gut by osmotic effect. Patients increasingly using these products on a GLP-1 (to satisfy sweet cravings with fewer calories) can trigger diarrhea unknowingly. The dose threshold varies, but 10 to 20 grams of sorbitol typically causes diarrhea in most adults.

Lactose. Patients with mild lactose intolerance may tolerate small amounts before treatment but find that GLP-1 therapy unmasks their sensitivity. The altered gut transit changes the threshold.

Fructose. Large fructose loads (fruit juice, agave, honey, high-fructose products) can produce diarrhea in patients with fructose malabsorption.

Alcohol. Both directly irritating to the gut and a common trigger of diarrhea after the night before.

Caffeine. Coffee particularly can produce a gastrocolic response that triggers diarrhea, especially on an empty stomach.

Keeping a brief food diary for 1 to 2 weeks often identifies specific triggers. Most patients can manage diarrhea by avoiding their top 3 triggers without overhauling their diet.

Lactose, fructose, and sugar alcohol contributions

The "low FODMAP" framework (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, And Polyols) is useful for thinking about diarrhea triggers on a GLP-1. Many GLP-1-related diarrhea cases improve substantially with low-FODMAP eating:

FODMAP category	Examples	Effect
Fructose	Honey, agave, mangoes, large fruit servings	Osmotic diarrhea
Lactose	Milk, soft cheeses, cream	Diarrhea in intolerant patients
Polyols	Sorbitol, xylitol, erythritol	Osmotic diarrhea
Fructans	Garlic, onion, wheat in large amounts	Gas, bloating, sometimes diarrhea
Galactans	Beans, lentils in large amounts	Gas, bloating

A short trial of low-FODMAP eating (2 weeks) followed by structured reintroduction can identify which categories are causing problems. A registered dietitian can guide this process.

Management: dietary, OTC, and prescription

The general algorithm for GLP-1-related diarrhea:

Dietary first line:

• Identify and avoid the top 2 to 3 triggers
• Reduce overall fat intake to under 20% of calories
• Eliminate sugar alcohols
• Try lactose-free dairy for 2 weeks to test for contribution
• Smaller, more frequent meals
• Adequate hydration with electrolytes

Over the counter:

• Loperamide (Imodium) 4 mg initially, then 2 mg after each loose stool, up to 8 mg daily
• Psyllium husk paradoxically helps diarrhea by absorbing excess water in the colon; 1 tbsp daily
• Electrolyte solutions for replacing losses
• Avoid bismuth subsalicylate long-term due to salicylate accumulation

Prescription if persistent:

• Dose reduction of the GLP-1 medication
• Cholestyramine for suspected bile acid diarrhea
• Pancreatic enzyme replacement for severe fat-related diarrhea
• Evaluation for other causes if symptoms persist

When diarrhea is something else

Not every diarrhea episode on Ozempic is caused by Ozempic. Concurrent conditions to consider:

• Infectious gastroenteritis (acute onset, fever, possibly contacts with similar symptoms)
• C. difficile infection in patients recently on antibiotics
• Inflammatory bowel disease (blood in stool, weight loss beyond expected, systemic symptoms)
• Celiac disease (gluten sensitivity, often with iron deficiency)
• Microscopic colitis (chronic watery diarrhea, often in older patients on PPIs or NSAIDs)
• Bile acid diarrhea (watery diarrhea, often urgent, sometimes post-cholecystectomy)
• Carbohydrate malabsorption (specific to certain foods)

Features that warrant evaluation: blood in stool, fever, weight loss exceeding the expected GLP-1 trajectory, night-time symptoms that wake the patient, or symptoms that started before the medication.

The tirzepatide comparison

Tirzepatide diarrhea rates from SURMOUNT-1:

Dose	Diarrhea incidence
5 mg	~19%
10 mg	~21%
15 mg	~23%
Placebo	~9%

The rates are roughly similar to semaglutide, though somewhat lower in the head-to-head comparison. The pattern, management, and triggers are essentially identical between the two medications.

Hydration and electrolyte considerations

Diarrhea produces fluid and electrolyte losses that compound the already-reduced intake on a GLP-1. Monitoring for dehydration is important.

Replacement strategy:

• Target 2 to 3 liters of fluid daily plus replacement for active losses
• Use oral rehydration solutions (Pedialyte, Liquid IV, similar) for severe or prolonged episodes
• Add sodium (broth, salted foods), potassium (banana, potato, coconut water), and magnesium (almonds, leafy greens) to daily intake
• Avoid sugary sodas as primary rehydration; they can worsen osmotic diarrhea

Signs of significant dehydration warrant medical evaluation: lightheadedness on standing, dark urine, decreased urination, dry mouth, lethargy.

Decision framework

Mild diarrhea (2 to 3 loose stools daily, no other symptoms): Dietary modification, identify triggers, hydration. Usually resolves within 1 to 2 weeks.

Moderate diarrhea (3 to 5 loose stools daily, some urgency): Above plus loperamide as needed. Reduce fat content further. Consider trial of low-FODMAP for 2 weeks.

Persistent diarrhea (more than 2 weeks despite intervention): Contact prescriber. Consider dose reduction. Consider workup for alternative causes if features warrant.

Severe diarrhea (more than 5 stools daily, signs of dehydration, or with concerning features): Medical evaluation. Possible temporary medication pause.

FAQ

Does Ozempic cause diarrhea?

Yes, in about 31.5% of users on the 2.4 mg dose per STEP 1.

Is diarrhea worse than constipation on Ozempic?

Constipation is more common; diarrhea can be more disruptive when it occurs.

Can I take Imodium?

Yes, occasional use is safe. Avoid prolonged daily use.

When will the diarrhea stop?

Usually within 4 to 6 weeks of dose stabilization for most patients.

Should I stop the medication?

Rarely necessary. Dose reduction is usually sufficient if diarrhea persists.

What foods help?

Bland low-fat foods: white rice, toast, banana, plain chicken, plain Greek yogurt.

Is bile acid diarrhea common on Ozempic?

Underdiagnosed but possible. Suspect if watery diarrhea is sudden and urgent; responds to cholestyramine.

Are tirzepatide and Ozempic different for diarrhea?

Similar rates and pattern; individual response varies.

Related guides

• Does Ozempic Cause Body Odor? Walking Through the Causation Question Honestly
• Does Ozempic Cause Blindness? The NAION Signal, Honestly Explained
• Does Ozempic Cause Cancer? Separating the Boxed Warning, the Rodent Data, and the Human Evidence
• Does Ozempic Cause Hair Loss? What the Trial Data Actually Shows
• Does Ozempic Cause Constipation? The Mechanism and the Fix

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
3. Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motility. Exp Diabetes Res. 2011;2011:279530.
4. Camilleri M, Sellin JH, Barrett KE. Pathophysiology, Evaluation, and Management of Chronic Watery Diarrhea. Gastroenterology. 2017;152(3):515-532.
5. Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol. 2009;7(11):1189-1194.
6. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67-75.
7. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021;12:645563.
8. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. Most recent revision 2024.
9. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. Most recent revision 2024.
10. American Gastroenterological Association. Clinical Decision Support Tool: Chronic Diarrhea. 2022.
11. Schiller LR, Pardi DS, Sellin JH. Chronic Diarrhea: Diagnosis and Management. Clin Gastroenterol Hepatol. 2017;15(2):182-193.

Footer disclaimers

Platform Disclaimer. FormBlends is a telehealth provider. Material in this article is informational and not a substitute for personalized clinical guidance. Persistent diarrhea warrants discussion with your prescriber.

Compounded Medication Notice. Compounded semaglutide and tirzepatide formulations are prepared at 503A pharmacies and are not FDA-approved. Side effect profiles may resemble but are not identical to branded products.

Results Disclaimer. Diarrhea response to dietary and pharmacologic interventions varies. Some patients have prolonged or severe symptoms requiring medical management; others have minimal symptoms.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Imodium is a registered trademark of Johnson & Johnson Consumer Inc. FormBlends has no affiliation with these companies.